Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. by Griffiths, B & Kew, KM
Cochrane Database of Systematic Reviews
Intravenousmagnesium sulfate for treating children with
acute asthma in the emergency department (Review)
Griffiths B, Kew KM
Griffiths B, Kew KM.
Intravenous magnesium sulfate for treating children with acute asthma in the emergency department.
Cochrane Database of Systematic Reviews 2016, Issue 4. Art. No.: CD011050.
DOI: 10.1002/14651858.CD011050.pub2.
www.cochranelibrary.com
Intravenous magnesium sulfate for treating children with acute asthma in the emergency department (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
5BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
14DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
16AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
17ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
17REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
29DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 IV MgSO4 versus placebo, Outcome 1 Hospital admissions. . . . . . . . . . . 29
Analysis 1.2. Comparison 1 IV MgSO4 versus placebo, Outcome 2 ED treatment time (minutes). . . . . . . . 30
Analysis 1.3. Comparison 1 IV MgSO4 versus placebo, Outcome 3 Return to ED within 48 hours. . . . . . . 30
Analysis 1.4. Comparison 1 IV MgSO4 versus placebo, Outcome 4 Hospital length of stay (hours). . . . . . . 31
31ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
33APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
35CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
35DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
35SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
36DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
iIntravenous magnesium sulfate for treating children with acute asthma in the emergency department (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Intravenous magnesium sulfate for treating children with
acute asthma in the emergency department
Benedict Griffiths1, Kayleigh M Kew2
1Evelina LondonChildren’sHospital, St Thomas’Hospital, London,UK. 2PopulationHealth Research Institute, StGeorge’s, University
of London, London, UK
Contact address: KayleighMKew, Population Health Research Institute, St George’s, University of London, Cranmer Terrace, London,
SW17 0RE, UK. kkew@sgul.ac.uk.
Editorial group: Cochrane Airways Group.
Publication status and date: New, published in Issue 4, 2016.
Review content assessed as up-to-date: 23 February 2016.
Citation: Griffiths B, Kew KM. Intravenous magnesium sulfate for treating children with acute asthma in the emergency department.
Cochrane Database of Systematic Reviews 2016, Issue 4. Art. No.: CD011050. DOI: 10.1002/14651858.CD011050.pub2.
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Acute asthma in children can be life-threatening and must be treated promptly in the emergency setting. Intravenous magnesium sulfate
is recommended by various guidelines for cases of acute asthma that have not responded to first-line treatment with bronchodilators
and steroids. The treatment has recently been shown to reduce the need for hospital admission for adults compared with placebo, but
it is unclear whether it is equally effective for children.
Objectives
To assess the safety and efficacy of intravenous magnesium sulfate (IV MgSO4) in children treated for acute asthma in the emergency
department (ED).
Search methods
We identified studies by searching the Cochrane Airways Review Group Specialised Register up to 23 February 2016. We also searched
ClinicalTrials.gov and reference lists of other reviews, and we contacted study authors to ask for additional information.
Selection criteria
We included randomised controlled trials of children treated in the ED for exacerbations of asthma if they compared any dose of IV
MgSO4 with placebo.
Data collection and analysis
Two review authors screened the results of the search and independently extracted data from studies meeting the inclusion criteria. We
resolved disagreements through discussion and contacted study authors in cases of missing data and other uncertainties relating to the
studies.
We analysed dichotomous data as odds ratios and continuous data as mean differences, both using fixed-effect models. We assessed
each study for risk of bias and rated the quality of evidence for each outcome with GRADE and presented the results in a ’Summary
of findings’ table. There was insufficient evidence to conduct the planned subgroup analyses.
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Main results
Five studies (182 children) met the inclusion criteria, and four contributed data to at least one meta-analysis. The included studies were
overall at low risk of bias, but our confidence in the evidence was generally low, mainly due to the small sample sizes. Treatment with IV
MgSO4 reduced the odds of admission to hospital by 68% (odds ratio (OR) 0.32, 95% confidence interval (CI) 0.14 to 0.74; children
= 115; studies = 3; I2 = 63%). This result was based on data from just three studies including 115 children. Meta-analysis for the
secondary outcomes was extremely limited by paucity of data. We performed meta-analysis for the outcome ’return to the emergency
department within 48 hours’, which showed a very imprecise effect estimate that was not statistically significant (OR 0.40, 95% CI
0.02 to 10.30; children = 85; studies = 2; I2 = 0%). Side effects and adverse events were not consistently reported and meta-analysis
was not possible, however few side effects or adverse events were reported.
Authors’ conclusions
IV MgSO4 may reduce the need for hospital admission in children presenting to the ED with moderate to severe exacerbations of
asthma, but the evidence is extremely limited by the number and size of studies. Few side effects of the treatment were reported, but
the data were extremely limited.
P L A I N L A N G U A G E S U M M A R Y
Do magnesium sulfate infusions reduce the need for hospital admission in children with acute asthma?
Background
Many children experience life-threatening asthma attacks and require treatment in the hospital emergency department. Some national
and international asthma treatment guidelines recommend giving an infusion of a drug called magnesium sulfate (IV MgSO4) to
children having asthma attacks that have not responded well to other treatments. This has been shown to reduce the need for hospital
admission for adults, but it is unclear whether it is safe and similarly effective for children.
Study characteristics
We found five studies in children that compared an infusion of MgSO4 to a placebo infusion when other treatments had not relieved
the attack (usually inhaled bronchodilators, steroids, and sometimes oxygen). These five studies included a total of 182 children. Only
three of the studies reported the outcome we were most interested in, which was the need to be admitted to hospital. The studies were
published between 1996 and 2000; these were the most current studies we could find when we searched in February 2016.
Key results and quality of the evidence
Fewer children who had an infusion of MgSO4 needed to be admitted to hospital compared with placebo. In fact, for every five children
treated with the MgSO4, one admission to hospital was prevented. However, the included studies were small, with only 115 children
in the main analysis, and the results did vary, so we cannot be absolutely sure of the benefits and harms. As there were so few studies,
we also could not tell whether the reduction in hospital admissions was associated with age, severity of the asthma exacerbation, or
whether it made a difference what other treatments were given. There were no reports of harm when the children received MgSO4.
The review therefore supports the use of MgSO4 in children, however it must be noted that the evidence for its use is very weak.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
M gSO4 compared to placebo for treating children with acute asthma in the emergency department
Patient or population: children with acute asthma in the emergency department
Settings: emergency departments
Intervention: MgSO4
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo M gSO4
Hospital admissions 767 per 1000 513 per 1000
(315 to 709)
OR 0.32
(0.14 to 0.74)
115
(3 studies)
⊕⊕©©
low1,2
MgSO4 reduced hospi-
tal admissions, but low
conf idence due to in-
consistency and small
numbers
Random-ef fects sensi-
t ivity analysis:
OR 0.18, 95% CI 0.02 to
1.59
ED treatment time
(minutes)
The mean ED treatment
t ime in the placebo
group was
96 minutes
The mean ED treatment
t ime in the intervent ion
group was
5 minutes more
(24 less to 34 more)
- 27
(1 study)
⊕⊕©©
low3
No clear benef it of
MgSO4.
Based on the subset
of children who were
discharged home, not
those who were admit-
ted
Return to ED within 48
hours
22 per 1000 9 per 1000
(0 to 186)
OR 0.4
(0.02 to 10.3)
85
(2 studies)
⊕⊕©©
low3
No clear benef it of
MgSO4
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Hospital length of stay
(hours)
The mean hospital
length of stay (hours) in
the placebo group was
18.9 hours
The mean hospital
length of stay (hours) in
the intervent ion group
was
5.3 hours lower
(9.46 to 1.14 lower)
- 47
(1 study)
⊕⊕©©
low4,5
Possible benef it of
MgSO4 but based on 1
small study
4 of the planned outcomes were not reported in a way that could be meta-analysed in any of the included studies (intensive care admissions, vital signs, spirometry,
validated paediatric symptom scores, and adverse events)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed
risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; ED: emergency department; OR: odds rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Test for heterogeneity P = 0.07, I2 = 63% (-1 inconsistency).
2Total number of children included in analysis low with concurrent low event rate, and a sensit ivity analysis using random
ef fects seriously reduced the precision of the est imate (-1 imprecision).
3Very imprecise est imate based on data f rom a single small study. ’Return to ED within 48 hours’ analysis included two
studies, but Ciarallo 1996 did not observe any events (-2 imprecision).
4Only study included lim it ing the precision of the result (-1 imprecision).
5Two other studies reported hospital admission but not length of hospital stay (-1 publicat ion bias).
4
In
tra
v
e
n
o
u
s
m
a
g
n
e
siu
m
su
lfa
te
fo
r
tre
a
tin
g
c
h
ild
re
n
w
ith
a
c
u
te
a
sth
m
a
in
th
e
e
m
e
rg
e
n
c
y
d
e
p
a
rtm
e
n
t
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
B A C K G R O U N D
Description of the condition
Asthma is a chronic respiratory condition characterised by inflam-
mation of the airways and partially reversible airflow obstruction.
Common symptoms include cough, wheezing, difficulty breath-
ing, reduced exercise tolerance, and chest tightness. In asthma air-
way inflammation and bronchospasm (contraction of the smooth
muscle lining the airways) leads to airflow obstruction. The con-
dition follows a varying course in individuals that is driven by ge-
netic and environmental triggers.
Asthma symptoms vary in severity and frequency. It can cause daily
chronic symptoms and exacerbations. An exacerbation is defined
as an acute worsening of asthma symptoms. Principles of treat-
ment consist of controlling daily symptoms and preventing exac-
erbations by providing good education and appropriate inhaler us-
age. National and international guidelines have been published for
the treatment of asthma exacerbations (BTS/SIGN 2014; GINA
2015).
Short-acting bronchodilators are given to relieve bronchospasm,
and symptoms of inflammation are treated with corticosteroids;
both are usually delivered via inhalers. Depending on the persis-
tence of symptoms, inhalers can be taken regularly (maintenance
therapy) or on an as-needed basis (reliever therapy) (BTS/SIGN
2014; GINA 2015). Beta2-agonists are recognised as most effec-
tive in relieving bronchospasm (Teoh 2012), however anticholin-
ergic inhalers have also proved effective in the treatment of acute
asthma (Griffiths 2013).
Children with asthma are most often managed in primary care,
however, in severe cases, secondary-level care by a paediatrician
may be necessary. The goal of treatment is to allow a good quality
of life while avoiding asthma exacerbations that require a visit to
the emergency department (ED) and hospital admission.
In severe exacerbations, which can be life-threatening, further
medications may be required, such as oral or intravenous corticos-
teroids (BTS/SIGN 2014; GINA 2015; Rowe 2001). Intravenous
bronchodilators and magnesium sulfate have also been used to
treat children with severe asthma exacerbations.
Description of the intervention
Recent clinical guidelines advise that a single dose of intravenous
magnesium sulfate (IV MgSO4) can be considered for children
5 years of age and older with acute severe asthma who have not
responded to inhaled bronchodilator therapy and for those with
life-threatening or near-fatal asthma (BTS/SIGN 2014).
Magnesium sulfate (MgSO4) has been used in a nebulised form in
the treatment of acute severe asthma; this is the subject of a separate
review, which found no significant reduction in hospital admission
(Powell 2012). For the purposes of this review, we have considered
only the use of IV MgSO4. Dosage in children is usually based
on weight. The British National Formulary for Children advises
40 mg/kg and up to a maximum total dose of 2 g, delivered by
intravenous infusion over 20 minutes. However, larger doses of up
to 75 mg/kg have been used (Scarfone 2000).
How the intervention might work
The mechanism of action of IV MgSO4 in the context of an
exacerbation of asthma is not fully understood. It is believed to
play a role in bronchial smooth muscle relaxation via its ability to
stop calcium ion movement into smooth muscle cells by blocking
the voltage-dependent calcium channels (Spivey 1990). Some ev-
idence has also been found of its role in reducing the inflamma-
tory response (Cairns 1996). The combination of smooth muscle
relaxation and anti-inflammatory properties provides a theoretical
basis for the use of MgSO4 in cases of acute asthma.
Why it is important to do this review
One in 11 children in the UK suffer from asthma. Asthma pre-
sentations in EDs are common, peaking at 26,969 admissions in
2006/2007 (Millet 2013). A total of 216 deaths from asthma were
reported in the UK in 2014; 16 of these individuals were children
14 years of age or younger (Asthma UK). In fact, between 2005
and 2010, 1% to 4.2% of all admissions to paediatric intensive
care units (PICUs) in theUKwere due to asthma; this translates to
1640 admissions (in 1410 patients). Furthermore, the number of
admissions to PICUs in the UK due to asthma is rising. Asthma-
related admissions increased by 67% (195 to 327 admissions) be-
tween 2005 and 2010 (Nyman 2011).
Historically, MgSO4 is a treatment used in the ED. The National
Review of Asthma Deaths reviewed 195 deaths from asthma be-
tween Febuary 2012 to January 2013 and found that 45% had at-
tended an ED prior to death (NRAD 2014). When these patients
present with life-threatening episodes of asthma, we need effective
and safe treatments.
Although current guidelines advocate the use of IV MgSO4 in
the treatment of acute asthma (BTS/SIGN 2014; GINA 2015),
it is acknowledged that evidence in the literature has provided
conflicting results. An earlier version of this review, Rowe 2000,
found little evidence to support the use of IV MgSO4 in children
based on results from seven studies, five of which studied adult
participants.
The burden of asthma in children continues to increase and as
such it is important to be able to guide treatment based on paedi-
atric evidence. As such, the previous review, Rowe 2000, has been
split into adult, Kew 2014, and paediatric reviews, focusing the
discussion and conclusions to the respective patient groups. This
review has provided the opportunity to review any new evidence
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that has emerged over the past 16 years and draw conclusions rel-
evant to current paediatric practice.
O B J E C T I V E S
To assess the safety and efficacy of intravenous magnesium sulfate
(IV MgSO4) in children treated for acute asthma in the ED.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials of any follow-up dura-
tion. We included studies reported as full text, those published as
abstract only, and unpublished data.
Types of participants
We included studies of children (18 months to 18 years of age)
treated in the ED for acute asthma (all severities). When studies
recruited both adults and children, we only used data if provided
for children separately. As wheezy symptoms in children younger
than 18 months may represent a different disease process (that
is bronchiolitis), we examined participant demographics in trials
that included children younger than 18 months to determine per-
centage of the study population. If they made up more than 10%
of the population, we excluded the studies.
Types of interventions
We included studies comparing any dose of IV MgSO4 versus
placebo. Because children with acute asthma often require addi-
tional treatments, we included studies that allowed other medica-
tions provided they were not part of the randomly assigned treat-
ment.We did not include studies of MgSO4 combined with other
intravenous bronchodilator agents unless the study set out to test
the effect of MgSO4, and all other treatments were the same in
both groups. We did not intend to assess IV MgSO4 against neb-
ulised MgSO4 or other active treatments. We have presented the
results in a summary characteristics table that includes a list of
medications given in each of the included studies (Table 1).
Types of outcome measures
Primary outcomes
1. Hospital admissions.
Secondary outcomes
1. ED treatment duration.
2. Intensive care admissions.
3. Hospital length of stay.
4. Vital signs (respiratory rate, oxygen saturations).
5. Spirometry (peak expiratory flow rate (PEFR), forced
expiratory volume in one second (FEV1)).
6. Validated paediatric symptom scores.
7. Adverse events.
Reporting in the study one or more of the outcomes listed here
was not an inclusion criterion for the review.
Search methods for identification of studies
Electronic searches
We identified trials from the Cochrane Airways Group Specialised
Register (CAGR), which is maintained by the Information Spe-
cialist for the Group. The Register contains trial reports identified
through systematic searches of multiple bibliographic databases
and by handsearching of respiratory journals andmeeting abstracts
(see Appendix 1 for further details). We searched all records in
the CAGR using the search strategy provided in Appendix 2. The
most recent search was conducted on 23 Februray 2016.
We also
conducted a search of ClinicalTrials.gov (www.ClinicalTrials.gov)
and the World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP) (www.who.int/ictrp/en/). We
searched all databases from their inception to the present, and im-
posed no restriction on language of publication.
Searching other resources
We checked reference lists of all primary studies and review arti-
cles for additional references.We searched relevant manufacturers’
websites for trial information. We also searched for errata or re-
tractions from included studies published in full text on PubMed
(www.ncbi.nlm.nih.gov/pubmed) on 8 April 2016.
Data collection and analysis
Selection of studies
Two review authors (BG and KMK) independently screened titles
and abstracts of all citations identified by the search for inclusion
and coded them as ’retrieve’ (eligible or potentially eligible/un-
clear) or ’do not retrieve’. We retrieved the full-text study reports/
publications, and both review authors independently screened the
full text and identified studies for inclusion. We identified and
recorded reasons for exclusion of ineligible studies. We resolved
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disagreements through discussion, or, if required, by consulting a
third person. We identified and excluded duplicates and collated
multiple reports of the same study, so that each study rather than
each report was the unit of interest in the review. We recorded the
selection process in sufficient detail to complete a PRISMA flow
diagram and a Characteristics of excluded studies table.
Data extraction and management
To record study characteristics and outcome data, we used a data
collection form that had been piloted on at least one study in the
review. One review author (KMK) extracted study characteristics
from the included studies, and both review authors independently
extracted outcome data. We extracted the following study charac-
teristics.
1. Methods: study design, duration of observation and follow-
up, details of any ’run-in’ period, number of study centres and
locations, withdrawals, and date of study.
2. Participants: N, mean age, age range, gender, asthma
severity, diagnostic criteria, baseline lung function, inclusion
criteria, and exclusion criteria.
3. Interventions: intervention, dose, comparison, concomitant
and failed treatments, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial and notable conflicts of interest of
trial authors.
We noted in the Characteristics of included studies table if out-
come data were not reported in a usable way. We resolved dis-
agreements by consensus or by involving a third person. The two
review authors transferred data into the Review Manager (version
5.3) file together (RevMan 2014). We double-checked that data
had been entered correctly by comparing data presented in the
systematic review with information in the study reports. A second
review author (BG) spot-checked study characteristics for accu-
racy against the trial report.
Assessment of risk of bias in included studies
Both review authors independently assessed risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011), resolving dis-
agreements by discussion. We assessed the risk of bias according
to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We graded each potential source of bias as high, low, or unclear
and provided a quote from the study report together with a jus-
tification for our judgement in the ’Risk of bias’ table. We sum-
marised the ’Risk of bias’ judgements across different studies for
each of the domains listed. We considered blinding separately for
different key outcomes when necessary (for example for unblinded
outcome assessment, risk of bias for hospital admissions may be
very different than for a participant-reported scale). When infor-
mation on risk of bias related to unpublished data or correspon-
dence with a study author, we noted this in the ’Risk of bias’ table.
When considering treatment effects, we took into account the risk
of bias for studies that contributed to that outcome.
Assessment of bias in conducting the systematic
review
We conducted the review according to this published protocol and
have reported any deviations from it in the Differences between
protocol and review section of the systematic review.
Measures of treatment effect
We analysed dichotomous data as odds ratios and continuous data
as mean differences or standardised mean differences. If studies
reported several validated symptom measures, or if different scales
were reported across studies, we analysed the data as standardised
mean differences in one analysis to reduce measurement error and
enhance precision. We entered the presented data as a scale with
a consistent direction of effect. We narratively described skewed
data reported as medians and interquartile ranges.
We undertook meta-analyses only when this was meaningful (that
is when treatments, participants, and the underlying clinical ques-
tion were similar enough for pooling to make sense).
When multiple trial arms were reported in a single trial, we in-
cluded only the relevant arms. If two relevant comparisons from a
single study were combined in the same meta-analysis, we halved
the control group to avoid double-counting.
Unit of analysis issues
For dichotomous outcomes, we used participants rather than
events as the unit of analysis (that is number of children with any
adverse events rather than the total number of events).
Dealing with missing data
We contacted investigators or study sponsors to verify key study
characteristics and to obtain missing numerical outcome data
when possible (for example when we identified a study as an ab-
stract only). When this was not possible and the missing data were
thought to introduce serious bias, we explored the impact of in-
cluding such studies in the overall assessment of results by per-
forming a sensitivity analysis.
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Assessment of heterogeneity
We used the I² statistic to measure heterogeneity among the trials
in each analysis. When we identified substantial heterogeneity, we
reported this and explored possible causes by prespecified subgroup
analysis.
Assessment of reporting biases
We were not able to pool more than 10 studies, and so could not
create and examine a funnel plot to explore possible small-study
and publication biases. We considered the impact of unpublished
studies in the GRADE ratings for each outcome.
Data synthesis
We used a fixed-effect model and performed a sensitivity analysis
with random-effects when we observed significant heterogeneity
(I² greater than 30%).
Summary of findings table
We created a ’Summary of findings’ table for all five outcomes.
We used the five GRADE considerations (study limitations, con-
sistency of effect, imprecision, indirectness, and publication bias)
to assess the quality of a body of evidence as it relates to the studies
that contribute data to the meta-analyses for the prespecified out-
comes. We used methods and recommendations described in Sec-
tion 8.5 and Chapter 12 of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011), using GRADEpro GDT.
We justified all decisions to downgrade or upgrade the quality of
studies using footnotes, and made comments to aid readers’ un-
derstanding of the review when necessary.
Subgroup analysis and investigation of heterogeneity
Based on observations in previous versions of this review and to
focus recommendations about the appropriateness of the inter-
vention within specific patient groups, we planned the following
subgroup analyses.
1. Baseline severity of exacerbation (moderate, severe, life-
threatening*).
2. Age (≤ and > 5 years).
We used the formal test for subgroup differences in RevMan 2014
*As no singlemetric has been accepted for assessing asthma severity
in children, we planned to extract baseline data relevant to the
following severity criteria as stated in the recent asthma guidelines
(BTS/SIGN 2014).
1. Ability to speak and eat.
2. Breaths per minute.
3. Pulse.
4. Pulse oximetry.
5. Peak flow.
6. Arterial (oxygen saturation).
BG labelled study populations as moderate, severe, and life-threat-
ening based on available data. The judgements were not made by
an independent assessor as planned because we were not able to
perform the subgroup analysis, so classification was made for de-
scriptive purposes only. If additional studies allow the subgroup
analysis to be undertaken in a future update of this review, this
will be done by an assessor blinded to the study results.
Sensitivity analysis
We planned the following sensitivity analyses.
1. Studies at high risk of bias for blinding.
2. Studies including children < 18 months of age.
3. Unpublished data.
R E S U L T S
Description of studies
We have provided full details of the conduct and participant
characteristics of each included study in the Characteristics of
included studies table, and reasons for excluding full texts in the
Characteristics of excluded studies table.
Results of the search
We identified 139 records in the electronic database searches and
31 additional records by searching ClinicalTrials.gov. We removed
one duplicate record, screened 169 records, and excluded 143 by
looking at the titles and abstracts alone. We retrieved full texts for
the remaining 26, of which 18 were excluded for the following
reasons: ’no placebo group’ (n = 7), ’adult population’ (n = 6), ’in-
patient sample’ (n = 2), no asthma diagnosis (n = 1), awaiting clas-
sification because we were unable to locate the publication (Abd
El Kader 1997), and ongoing (NCT01522040). The remaining
eight citations related to five studies, which we included in the sys-
tematic review (Ciarallo 1996; Ciarallo 2000; Devi 1997; Gürkan
1999; Scarfone 2000). We have presented the study flow in Figure
1.
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Figure 1. Study flow diagram.
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Included studies
Five studies met all the inclusion criteria (Ciarallo 1996; Ciarallo
2000; Devi 1997; Gürkan 1999; Scarfone 2000), randomising
a total of 182 children presenting to the ED. Sample sizes were
small, ranging from 20 to 54 (median 31). We have provided a
summary of study characteristics in Table 1.
All of the included studies were randomised, double-blind,
placebo-controlled trials, which were conducted at between one
and three centres. Three studies were conducted in the USA
(Ciarallo 1996; Ciarallo 2000; Scarfone 2000), one in India (Devi
1997), and one in Turkey (Gürkan 1999). The main time of fol-
low-up measurement was not reported in Devi 1997, but in the
remaining four studies it ranged from 90 to 120 minutes after the
start of the infusion.
Inclusion and exclusion criteria varied across the five studies with
respect to age, severity metrics such as lung function and vital
statistics, and allowed and disallowed comedications. The mini-
mum age was 6 years in three studies, and 1 year in two studies
(Devi 1997; Scarfone 2000). The upper age for inclusion was 16
or 18 in all studies except Devi 1997, which used a maximum age
of 12 years.
We have provided a summary of the characteristics of children
included in the studies in Table 2, including mean age, percentage
male, and key measures of lung function and vital signs when they
entered the ED.
Across the five studies, 89 children were randomised to receive
MgSO4 and 93 to placebo. In four studies, between 25 and 75
mg/kg MgSO4 was administered over 20 minutes, and Devi 1997
gave 0.2 ml of 50% over 35 minutes (100 mg). The placebo was
always delivered in a matching saline infusion. The administration
of nebulised bronchodilators, usuallymultiple times, was common
across studies. All studies except Gürkan 1999 described the use of
corticosteroids, usually methylprednisolone, and two also stated
that oxygen had been used (Devi 1997; Scarfone 2000).
Three of the five studies reported the primary outcome (Ciarallo
1996; Ciarallo 2000; Scarfone 2000); the secondary outcomes
were generally poorly reported. No data could be analysed for
intensive care admissions, vital signs, spirometry, symptom scales,
or adverse events.
Excluded studies
We excluded 17 articles relating to 12 studies after viewing the
full texts. Bijani 2001, Bilaceroglu 2001, Boonyavorakul 2000, del
Castillo Rueda 1991, and Skobeloff 1989 were all included in the
adult review (Kew 2014); although these studies included some
participants under 18, they were classified as adult populations
and disaggregated data could not be obtained. Singhi 2011 and
Torres 2012 used the correct population and intervention and
were relatively large compared to the included studies (100 and
143 respectively), but these were open-label studies that did not
use a placebo comparison. Irazuzta 2016 studied children with
status asthmaticus and did not use a placebo comparison, and
Watanatham 2015 compared nebulised MgSO4 with IV MgSO4
without a placebo group. We excluded Santana 2001 because the
study recruited childrenwhohad already been admitted to a special
paediatric care unit before they were given IV MgSO4. Similarly,
Okayama 1987 recruited children from mixed settings, including
those already admitted to hospital, which could not be separated
from the children who met the inclusion criteria for this review.
The remaining study, Liang 1998, did not require that children
had a diagnosis of asthma to be included in the study.
Risk of bias in included studies
Overall, the risk of bias across the studies was low, with some
uncertainties relating to attrition and methods of allocation, and
some issues with selective reporting (Figure 2).
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
We rated no studies as having a high risk of bias for sequence
generation or allocation concealment. We rated only one study
as low risk for both selection bias domains (Ciarallo 2000), and
rated the other four as unclear in one domain, in Ciarallo 1996
and Scarfone 2000, or both domains, in Devi 1997 and Gürkan
1999.
Blinding
It is unlikely that biases related to insufficient blinding affected
the results. All studies used matched placebos and double-blind
procedures, although outcome assessor blinding was unclear in
one study that was only reported as a conference abstract (Gürkan
1999).
Incomplete outcome data
There were some uncertainties in this domain, but no study re-
ported drop-out rates that were high or unbalanced enough that
we considered it to be at high risk of bias. Two studies did not
report how many children were not accounted for in the analyses
(Ciarallo 2000; Gürkan 1999), and we rated the other three as at
low risk of bias (Ciarallo 1996; Devi 1997; Scarfone 2000).
Selective reporting
There was evidence of selective reporting in two studies conducted
by the same author (Ciarallo 1996; Ciarallo 2000). Both reported
some outcomes without variance, with inexact P values, or only
in graphs, meaning the data could not contribute to the meta-
analyses.We rated the other three studies as at low risk (Devi 1997;
Gürkan 1999; Scarfone 2000).
Other potential sources of bias
Ciarallo 1996 was terminated before the specified sample was
reached due to a change in ED practice (intravenous access was
used less frequently in the care of status asthmaticus), which slowed
the rate at which eligible patients were enrolled. There were also
baseline imbalances in lung function between the two groups,
which the study authors recognised may have magnified the dif-
ference between magnesium and placebo. We noted no additional
sources of bias in the other studies (Ciarallo 2000; Devi 1997;
Gürkan 1999; Scarfone 2000).
Effects of interventions
See: Summary of findings for the main comparison MgSO4
compared to placebo for treating children with acute asthma in
the emergency department
A summary of the main results, including absolute effects and an
assessment of the quality of the evidence, canbe found in Summary
of findings for the main comparison.
Primary outcomes
Hospital admissions
Treatment with IVMgSO4 reduced the odds of admission to hos-
pital by 68% (odds ratio (OR) 0.32, 95% confidence interval (CI)
0.14 to 0.74; children = 115; studies = 3; I2 = 63%; Analysis 1.1).
This result was based on data from three studies including 115
children (Ciarallo 1996; Ciarallo 2000; Scarfone 2000). The result
was statistically significant (P = 0.008) but had a wide confidence
interval that estimated a true population reduction in admission
between 86% and 26%. In absolute terms, 767 out of 1000 peo-
ple given placebo needed a hospital admission, compared with
513 (95% CI 315 to 709) out of 1000 given IV MgSO4. This
translates to a number needed to treat for an additional beneficial
outcome of 4. There was statistically significant heterogeneity in
the analysis (I2 = 63%, P = 0.07) and a sensitivity analysis using
a random-effects model provided a much less precise result that
was not statistically significant (OR 0.18, 95% CI 0.02 to 1.59),
but the direction and size of the effect was still in favour of IV
MgSO4. The studies were of good methodological quality, how-
ever the small number of study participants and heterogeneity re-
duced our confidence in the result to low.
Secondary outcomes
Emergency department treatment duration
In the one study that reported data for duration of treatment in the
ED (Scarfone 2000), use of IV MgSO4 caused children to spend
an extra five minutes in the ED. However, the effect estimate was
very imprecise, and the result was neither statistically nor clinically
significant (mean difference (MD) 5.00, 95% CI -24.40 to 34.40;
children = 27; studies = 1; Analysis 1.2). We downgraded the
quality of this evidence twice for imprecision and rated as low
because just one small study contributed to the analysis.
12Intravenous magnesium sulfate for treating children with acute asthma in the emergency department (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Intensive care admissions
No studies reported admission to intensive care in a way that we
could include in our analyses.
Return to emergency department within 48 hours
We did not specify this outcome in the protocol for this systematic
review, but chose to present the results because it is related to other
named outcomes which were not well reported across the studies.
Two studies with 85 children reported data for this outcome (
Ciarallo 1996; Scarfone 2000), but one did not observe any events
and so did not contribute to a pooled effect. In both groups the
event rate was low, and the confidence intervals suggest a very
imprecise effect estimate that was not statistically significant (OR
0.40, 95% CI 0.02 to 10.30; children = 85; studies = 2; I2 =
0%; Analysis 1.3). The small number of studies and events in
this analysis resulted in a very imprecise estimate that warranted
downgrading the quality of evidence twice for imprecision and
rating as low.
Hospital length of stay
One study with 47 children reported data for this outcome (Devi
1997). Treatment with IV MgSO4 reduced the length of hospital
admission by 5.3 hours (MD -5.30, 95% CI -9.46 to -1.14; chil-
dren = 47; studies = 1; Analysis 1.4). The effect estimate was im-
precise but favours the treatment group at each extreme, and the
result was statistically significant. Again this analysis was based on
one study with very few children; we also downgraded for publi-
cation bias because two other studies reported hospital admission
but not length of hospital stay, rating the evidence as low quality.
Vital signs (respiratory rate, oxygen saturations)
No studies reported vital signs in a way that we could include in
our analyses. Devi 1997 reported oxygen saturations in graphical
form, therefore data could not be accurately collected, however
they did report a statistically significant difference favouring the
treatment group. Examining the graph the effect was seen from 0
to 15 hours postinfusion.
Spirometry
No studies reported peak expiratory flow rate (PEFR) or forced
expiratory volume in one second (FEV1) in a way that we could
include in our analyses. Ciarallo 1996 reported the outcome for
FEV1, forced vital capacity (FVC), and PEFR as a statistical dif-
ference between groups after treatment favouring the magnesium
group. Devi 1997 reported PEFR in graphical form, therefore data
could not be accurately collected, however they again reported a
statistically significant difference favouring the treatment group.
Examining the graph the effect was seen from0 to 15 hours postin-
fusion. Gürkan 1999 reported a significant increase in the mean
of percentage of improvement from baseline in PEFR at 30 min-
utes after initiation of magnesium infusion (P = 0.0002), and they
found an even greater improvement at the end of the observation
period (P = 0.0001). Ciarallo 2000 found the PEFR and FEV1
improvement from baseline was statistically greater in the group
that had received IV MgSO4. They reported that this effect was
apparent at all study time points.
Validated paediatric symptom scores
No studies reported validated asthma symptom scores. Gürkan
1999 reported a significant change in mean clinical asthma score
of the children in themagnesium group at 90minutes (P = 0.005).
Ciarallo 2000 reported that there were statistically significant dif-
ferences in the clinical asthma scores between the two groups,
which occurred later in the study period at 95 minutes (1.4 IV
MgSO4 group versus 2.5 placebo group) and 110 minutes (1.1 IV
MgSO4 group versus 2.4 placebo group). Scarfone 2000 reported
a pulmonary index score at 7 points and found no statistical dif-
ference between groups (P = 0.37).
Adverse events
The included studies did not report enough data to enable meta-
analysis, however reviewing the narrative results revealed a low in-
cidence of adverse events in both groups. Gürkan 1999 reported
no significant difference in side effects (but did not report which
symptoms this included) and no significant difference in heart
rate or blood pressure. Scarfone 2000 reported no episodes of hy-
potension in either group and no difference between groups in
degree of tachycardia. Only one child in the placebo group experi-
enced emesis. Ciarallo 2000 reported no intergroup difference in
systolic blood pressure. Ciarallo 1996 also reported no difference
in blood pressure. They did state that two children in the treat-
ment group reported a relaxed sensation compared to none in the
placebo group. There were no reports of dizziness, fatigue, or any
other adverse symptoms.
Devi 1997 reported the following adverse effects in the treatment
group: epigastric warmth (12.5%), pain (16.6%), and tingling and
numbness (12.5%) at the site of infusion. There were no reported
incidents of these symptoms in the control group.
Subgroup and sensitivity analyses
Since there were only three studies in the primary analysis (and
fewer in the secondary), we did not consider the planned subgroup
analyses on the basis of baseline severity of exacerbation and age
to be justified. Similarly, we were unable to conduct the planned
sensitivity analyses to test the robustness of the results in relation
to detection bias, the inclusion of very young children, and un-
published data.
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D I S C U S S I O N
Summary of main results
Children with predominantly moderate to severe asthma present-
ing to the ED who were treated with IV MgSO4 in addition to
standard therapy showed a 68% reduction in the odds of hospital
admission (OR 0.32, 95% CI 0.14 to 0.74). This result represents
a dramatic reduction in admission rates, however confidence in
the result was low due to the small number of children included
in the analysis (n = 115) and variability between study results.
The variability in study results was reflected in the estimate of
heterogeneity for the primary outcome. Examining the primary
analysis, the data from Scarfone 2000 appears to lie outside those
reported in the other two studies. It is difficult to explain the
heterogeneity, as the studies were very similar in design and study
population included. All of the studies were relatively small in size,
increasing the imprecision in the reporting of effects. Repeating
the analysis using a random-effects model gave a result that was
not statistically significant (OR 0.18, 95% CI 0.02 to 1.59). This
again highlights that although the results favour the use ofMgSO4,
the strength of that conclusion is very limited.
Data for the secondary outcomes was also limited. Two studies
provided data for the outcome ’return to the emergency depart-
ment within 48 hours’ (Ciarallo 1996; Scarfone 2000), which
favoured IV MgSO4, but the confidence intervals did not exclude
no difference (OR 0.40, 95%CI 0.02 to 10.30). Several studies re-
ported improvements in spirometric data with treatment, but did
not include the raw data for meta-analysis. The message from the
narrative description of results for symptoms score and spirometry
in all but one case favoured treatment with IV MgSO4. However,
interpreting these results requires even greater caution.
Traditionally asthma has been referred to in the literature in terms
of severity, and as such national guidelines are often framed in this
manner. We intended to perform a subgroup analysis by severity
subgroup. We had proposed to get a blinded review author to
rate the severity of each study based on the inclusion criteria,
but the limited amount of available data prevented this subgroup
analysis. However, examining the inclusion criteria for the three
studies that presented data for the primary outcome (Ciarallo
1996; Ciarallo 2000; Scarfone 2000), we can see that all children
had a peak expiratory flow (PEF) less than 70%, which would have
traditionally been referred to as moderate to severe exacerbations.
While the evidence is based on a moderate-to-severe cohort, it is
acknowledged that severity in paediatric practice is often a clinical
judgement as spirometry in young children is frequently limited
in its accuracy.
Again, data on side effects was inconsistently reported, which lim-
ited the meta-analysis, but on the whole the number of side ef-
fects was small. In fact, the only reported side effect was a relaxed
sensation in two children (Ciarallo 1996). There was no reported
evidence of the haemodynamic instability that is often historically
reported with the use of MgSO4. The lack of any reported harm
is encouraging, but the ability to extrapolate this result is again
limited by the small number of studies included in the review.
If we accept that there is weak evidence of the effectiveness of
MgSO4, the question of timing of administration needs to be ad-
dressed. The included study protocols administered IV MgSO4
after failure to improve with first-line nebulised bronchodilator
therapy. We would agree that MgSO4 remains a second-line ther-
apy after patients have failed to respond to more evidence-based
nebulised bronchodilator therapies. In clinical practice IVMgSO4
is often used in conjunction with other IV bronchodilators (salbu-
tamol and aminophylline). As the studies included in this review
only examined MgSO4 as a single IV agent, evaluating any possi-
ble synergistic interaction was beyond the scope of this review.
Overall completeness and applicability of
evidence
Three studies contributed data to the primary outcome assessing
the potential effect of IV MgSO4 on preventing hospital admis-
sion (Ciarallo 1996; Ciarallo 2000; Scarfone 2000). The studies
used between 25 and 75 mg/kg of MgSO4, but all were given
in a 20-minute infusion. We cannot comment on optimal dos-
ing given the limited data in the review; at this time it would be
prudent to comply with national guidance which is in line with
the range in this review. All three studies were conducted in the
USA, which has implications on the applicability of the evidence
to other healthcare systems, especially with regard to the comed-
ications administered previous to MgSO4. The US studies gave
children nebulised bronchodilators (albuterol, ipratropium bro-
mide, or both) and IV methylprednisolone, which may not be the
practice in other countries.
A common criticism of hospital admission as an outcome is that
the criteria to make this decision is often not standardised, and
it is widely acknowledged that admission rates vary by country
and even region. However, where randomisation is appropriate it
should provide a reliable between-group difference in moderate-
to-severe patients. Itmay be argued that severe asthma by its nature
requires admission to hospital, in which case admission to paedi-
atric intensive care unit (PICU) may be a possible outcome. How-
ever, it must also be acknowledged that in some institutions some
therapies mandate admission to a PICU (certain IV therapies),
in which case the need for intubation and mechanical ventilatory
support may represent an alternative. Rightly or wrongly, burden
of disease is widely reported as a rising admission rate, therefore it
stands to reason we should attempt to use this as an outcome of
treatment efficacy.
The children in the studies had a mean age of around 11 in
Ciarallo 1996 and Ciarallo 2000 and were younger on average
in Scarfone 2000, at around 7 in the active group and 5 in the
placebo group. Thismean age would support the recommendation
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in British Thoracic Society guidance, however younger children
were also included and treated safely in the studies.
The age imbalance within Scarfone 2000 may have affected the
results and suggests that the sample sizes of the included studies,
of which Scarfone 2000 is the largest at 54, are unlikely to have
been sufficiently large enough to assume that important baseline
variables were evenly distributed by randomisation. These differ-
ences and limitations in the design and conduct of the studies
contributing data means that the implications for practice must
be carefully considered.
No more than two studies contributed to any of the secondary
outcomes, and we were unable to conduct a meta-analysis for five
of the eight secondary outcomes. As such, even the three secondary
outcomes for which we could include data (duration in ED, re-
turn to ED within 48 hours, and duration of hospital stay) in-
cluded data for no more than 88 children, which severely limits
the applicability of any conclusions that can be drawn. Outcomes
that could not be supported by analyses included admission to
intensive care unit, spirometry, and adverse events, which we fully
expected to be better reported in studies conducted in an emer-
gency setting. For these outcomes, we tried to describe narratively
information in the studies that was not fully reported in order to
give the fullest picture possible, but they represent an important
gap in the evidence base.
Previous reviews have examined subgroups based on exacerbation
severity and concluded that IV MgSO4 has a role primarily in the
treatment of severe exacerbations. We have already alluded to the
difficulties of assessing asthma severity in children, but our results
are most applicable to children with moderate or severe asthma
attacks. This group of patients is more likely to present to the ED,
therefore we would agree that currently the role of IV MgSO4
would be inmoderate to severe patients who have failed to respond
to inhaled therapies, and not to children presenting in primary
care. Clinically MgSO4 is also used prior to or concurrently with
nebuliser therapy in severe life-threatening episodes where severe
obstruction to air flow limits the effectiveness of inhaled therapies.
Studies in this review did not test IV MgSO4 in these situations,
but we excluded a study recruiting children in status asthmaticus
that did not include a placebo group (Irazuzta 2016). Prioritisa-
tion of therapies in extremis needs to be based on sound clini-
cal judgement and experience. It is important to recognise that
asthma attacks run a continuum, often lapsing and relapsing over
several days, and what role magnesium has in altering the course
of an exacerbation is unknown.
Quality of the evidence
While there were some uncertainties in the study procedures, par-
ticularly with selection and attrition bias, we considered the in-
cluded studies to be of good methodological quality overall, and
so none of the outcomes were downgraded for risk of bias. Addi-
tionally, the five studies closely matched the inclusion criteria set
out in the protocol, therefore we did not consider the evidence to
be compromised by indirectness.
However, our confidence in the findings was reduced by serious
imprecision in the estimates, largely due to very small numbers
of studies and participants. In the case of the primary outcome,
serious differences in what the three studies found resulted in the
effect becoming imprecise when we performed a random-effects
sensitivity analysis, and this reduced our confidence in the main
finding.
Incomplete outcome reporting in two studies affected some of
the secondary outcomes that we were not able to meta-analyse
(spirometry, intensive care admissions, vital signs). As mentioned
above, the small number of included studies overall and the very
small amount of data suitable for meta-analysis may suggest pub-
lication bias, and limits the conclusions that can be drawn.
Potential biases in the review process
This review examined included studies for bias against predeter-
mined criteria as specified by current Cochrane methodology. We
identified internal reporting biases in two of the included studies
(Ciarallo 1996; Ciarallo 2000), which may have impacted on the
completeness of our results, but this was considered in the relevant
GRADE ratings. Ciarallo 1996 reported in their methodology a
wide range of parameters that were collected on participants but
only reported some of these outcomes, which all had significant
results. The authors stated that the trial recruitment period was
cut short because of a change in ED practice. Their original power
calculation stipulated 40 participants to detect a 25% difference
in PEFR; only 31 participants were enrolled, and as such the es-
timate of effect can be exaggerated. However, we did not include
PEFR in our meta-analysis, and so our results were not affected.
The authors also note there was a difference in the baseline char-
acteristic (FEV1) between the groups, which could again have led
to an overestimate of the effect in the treatment group.
We implemented the planned methods as far as possible, but in
some cases the small number of studies meant this was not possible
or valid. We have listed these instances in Differences between
protocol and review.
Agreements and disagreements with other
studies or reviews
Having urged caution in the interpretation of the primary analysis,
it can be seen that the result favouring admission reduction in
the IV MgSO4 group is in keeping with the recently published
adult review. A recent review of IVMgSO4 for acute asthma in the
ED in adult patients reported a reduction in the odds of hospital
admission of 25% (OR 0.75, 95% CI 0.60 to 0.92) based on 11
studies including 1769 participants (Kew 2014). This systematic
review of the adult evidence contains new data from the largest
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adult study to date (Goodacre 2013, n = 752). They also found
an improvement in spirometric parameters in participants treated
with IV MgSO4. An older Cochrane review that assessed adults
and children together only found a treatment effect in a severe
patient subgroup (Rowe 2000).
Caution is required in extrapolating results from adult asthma
studies, as childhood asthma is reported to respond differently to
some established therapies.
Cheuk 2005 published a meta-analysis of paediatric patients,
which reported hospital admission as its primary outcome. It in-
cluded four studies in this analysis, three of the studies presented
here and also admission data for Devi 1997 (admission data not
included in published article and was not made available despite
attempts to contact the study author). The meta-analysis con-
cluded that magnesium was likely to reduce hospital admission
and improve bronchospasm.
Most recently in the paediatric literatureOhn 2014 published a re-
view stating magnesium should be given to all children presenting
to hospital with acute severe asthma. This conclusion was based
on two meta-analyses that included adult and paediatric patients,
Rowe 2001 and Shan 2013, and one recent randomised controlled
trial, Torres 2012, which was excluded from this review as it com-
pared IV MgSO4 versus standard care and not placebo. Torres
2012 reported a statistically significant reduction in the need for
mechanical ventilation in the IV MgSO4 group.
MgSO4 can also be administered as an aerosol by nebuliser de-
vices. There has been increasing interest in its use in adults and
children with acute asthma, and a Cochrane review in 2012 found
no improvement in lung function and no decrease in hospital ad-
mission with its use (Powell 2012). A large paediatric randomised
controlled trial examining its use in children in the ED (N = 508)
was recently published (Powell 2013), and while the new study is
yet to be incorporated in to their Cochrane review (Powell 2012),
the study did not find a clinical difference in asthma severity score
and did not report hospital admission data. Admission to PICU/
high dependency unit was reported and was required by 35 out of
508 children (9% in the treatment group versus 6% in the placebo
group).
IV MgSO4 is commonly used in paediatric practice. In a survey
of 183 ED consultants in the UK and Ireland, 94.5% report us-
ing it in their management of acute wheeze, and nearly one-third
(28.4%) use it as their first-line intravenous agent (Lyttle 2015).
The overwhelming narrative from the paediatric and adult liter-
ature supports the use of IV MgSO4. This conclusion, while in
keeping with this review, has at times been based on a very lim-
ited evidence base. Despite the largest adult trial to date showing
no statistical difference, its inclusion in the most recent Cochrane
analysis has provided a more robust base for the use of IV MgSO4
in adults. In paediatric practice the literature has often drawn from
adult data and paediatric data not obtained from randomised con-
trolled trials. This review does draw a similar conclusion to the
previous paediatric meta-analysis, but highlights the very severe
limitations of the evidence.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
IVMgSO4 may reduce the need for hospital admission in children
presenting to the ED with moderate to severe exacerbations of
asthma, but the evidence is extremely limited by the number and
size of studies. There was a notable lack of data for many of the sec-
ondary outcomes, on which limited conclusions can be drawn (in-
tensive care admissions, length of hospital stay, vital signs, spirom-
etry, and symptom scales).
While the evidence of the efficacy of IVMgSO4 is low quality, the
meta-analyses and a narrative synthesis of adverse events suggest
it is unlikely to cause harm, however data were extremely limited.
Further analysis according to severity of exacerbation was not pos-
sible, but the evidence does not apply to mild exacerbations out-
side of the emergency setting.
Implications for research
The choice of outcome in paediatric clinical asthma trials is varied
and has often hampered our ability to combine and meta-analyse
data. Spirometry in young children is challenging, especially in the
acute situation, and linking data to morbidity is difficult. Multiple
asthma severity scores have been published, but few are validated,
and no one score is reported consistently in the literature. Despite
the number of asthma deaths remaining unacceptably high, the
numbers are too low for mortality to be a useful outcome in pae-
diatric trials. We therefore reported hospital admission data as the
primary outcome. Widespread use of internationally agreed core
outcome sets would facilitate future meta-analyses.
Studies in asthma have often framed treatment by severity. Mea-
suring severity in the ED is problematic and may be best assessed
clinically. Where the outcome is hospital admission, the event rate
is obviously higher in the severe group, and it is therefore easier
to detect a between-group difference in this subset of patients.
These analyses are often secondary analyses, and the studies are
not designed to power these analyses adequately. In the future it is
important to classify treatment by severity to power studies ade-
quately to detect these subgroup differences.Withholding therapy
from less severe attacks may mean missed opportunities to stop
the progression of an attack to severe or life-threatening.
The results of this review are in keeping with those from the recent
adult review, but there are inherent dangers in extrapolating adult
data to paediatric populations. At present, the use of IVMgSO4 is
under-reported in paediatric practice, and this review’s conclusions
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are based on results from three small studies. Only with more data
can we truly answer the question as to the efficacy of IV MgSO4,
and despite no new data in the last 16 years, we would argue that
clinical equipoise still exists. A subsequent trial should examine
the use of IV MgSO4 in paediatric populations using pragmatic
markers of severity and practical outcomemeasures not dependent
on spirometry.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ciarallo 1996
Methods Design: Randomised, double-blind, parallel-group, placebo-controlled trial
Urban paediatric emergency department in Boston, USA
Conducted from 20 September 1993 to 20 December 1994
Participants Participants: 31 participants were randomised to IV MgSO4 (15) and placebo (16)
Inclusion criteria: Children aged 6 to 18 years who were being treated for an acute
asthma exacerbation with PEFR less than 60% of the predicted value after receiving 3
beta-2 adrenergic nebuliser treatments
Exclusion criteria: Body temperature greater than 38.5 °C; systolic blood pressure at
less than the 25th percentile for age; recent use of theophylline; history of cardiac, renal,
or pulmonary disease; and pregnancy
Interventions Treatments:
1. IV MgSO4 25 mg/kg over 20 minutes
2. Saline infusion over 20 minutes
Comedications: 3 beta-2 adrenergic nebuliser treatments; intravenous methylpred-
nisolone infusion (2 mg/kg) was given to children who had not received corticosteroids
Timing of intervention: If PEFR was less than 60% of the predicted value after 3 nebu-
lised beta-2 adrenergic agents, and if themedical team caring for the child concluded that
intravenous access was necessary for further medical management, placebo or MgSO4
was then administered
Outcomes Vital signs, O2 saturations, PEFR, FVC, FEV1
Main follow-up 110 minutes after start of infusion
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed in blocks of
10 by the pharmacy department, using a
random-number table
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “assigned to receive magnesium sulfate (25
mg/kg; maximum, 2 gm in 100 ml of nor-
mal saline solution) or an equivalent vol-
ume of normal saline solution (placebo)
in a double-blind fashion”. The magne-
sium and placebo solutions were prepack-
aged by the hospital pharmacy in identi-
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Ciarallo 1996 (Continued)
cal containers that were coded according
to a randomised sequence. Themagnesium
solution was given in 100 ml of normal
saline solution to prevent the warm sensa-
tion at the intravenous line site described
when magnesium sulfate is infused undi-
luted, thus maintaining the masked proto-
col
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear if those taking measurements were
blind. All children had arrangements for
admission instituted at the time of enrol-
ment into the study, as decided by their
physicians, independent of the study. “In
this setting the discharge rate from the
emergency department was the rate at
which decisions to admit were reversed.”
“Criteria for discharge from the emergency
department included (1) SaO2 greater than
94%, (2) no evidence of respiratory distress
such as tachypnoea, flaring, or retractions,
(3) minimal to no wheezes on auscultation,
(4) PEFRgreater than70%of the predicted
value, and (5) normal cerebral function -
all maintained for 3 h after a nebulization”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No mention of non-completers
Selective reporting (reporting bias) High risk Only significant results were reported for
FEV1, PEFR, FVC. No data reported for
oxygen saturations, respiratory rates, length
of hospital stay, or blood pressure. Full re-
sults only graphical. PICU admission data
not reported
Other bias High risk The study was terminated before the speci-
fied sample was reached because of a change
in EDpractice (intravenous access was used
less frequently in the care of status asth-
maticus), which impaired the rate at which
eligible patients were enrolled
“magnesium group started with a lower
FEV1 gave this group more room for im-
provement, potentially magnifying differ-
ences in the rates of improvement in FEV1
between the two groups and overestimat-
ing the effect of magnesium in our study
population.”
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Ciarallo 2000
Methods Design: Randomised, double-blind, parallel-group, placebo-controlled trial
2 urban tertiary care paediatric emergency departments in the USA
Recruited from September 1996 to August 1997
Participants Participants: 30 participants were randomised to IV MgSO4 (16) and placebo (14)
Inclusion criteria: Children aged 6 to 17.9 who required 3 nebulised bronchodilating
treatments (albuterol or ipratropium bromide or a combination of the 2); PEFR less
than 70%
Exclusion criteria: Body temperature greater than 38.5 °C, use of theophylline within
the previousweek, and a history of cardiac, renal, or pulmonary disease other than asthma
Interventions Treatments:
1. IV MgSO4 40 mg/kg (maximum 2 g) over 20 minutes
2. Saline infusion over 20 minutes
Comedications: 3 nebulised bronchodilating treatments (albuterol or ipratropium bro-
mide or a combination of the 2). IV methylprednisolone (2 mg/kg) was administered to
children who had not yet received corticosteroids
Timing of treatment: If PEFR was less than 70% of the predicted value after 3 nebulised
bronchodilators, and if the medical team caring for the child perceived them to be
resistant to nebuliser, they received the placebo or MgSO4
Outcomes Change in PEFR, FEV1, and FVC; ED disposition; serial clinical asthma scores; BP;
deep tendon reflexes
Main follow-up 105 minutes after start of infusion
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was blocked in groups of
10
Allocation concealment (selection bias) Low risk Randomly assigned by the investigational
drug pharmacist
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The magnesium and placebo solutions
were prepared by the hospital pharmacy
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The physicians on the medical team acted
independently from the study physicians
and were blinded to the child’s magnesium
treatment status
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No mention of non-completers. 8 were ex-
cluded because of unacceptable spirometry
efforts (unclear which group, assumed pre-
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Ciarallo 2000 (Continued)
randomisation)
Selective reporting (reporting bias) High risk Lung function parameters were only re-
ported graphically or with no variance or
inexact P values in the text
Other bias Low risk None detected
Devi 1997
Methods Design: Randomised, double-blind, parallel-group, placebo-controlled trial
Pediatric Emergency Department of teaching hospital in India
Recruited from January 1994 to January 1995
Participants Participants: 47 participants were randomised to IV MgSO4 (24) and placebo (23)
Inclusion criteria: Children aged 1 to 12 with inadequate or poor response to initial 3
doses of nebulised salbutamol given at an interval of 20 minutes over a period of 1 hour,
and (ii) where a written consent could be obtained from the parents accompanying the
child
Exclusion criteria: Children with axillary temperature greater than 38 °C, and (ii) blood
pressure less than 50th percentile for age
Interventions Treatments:
1. IV MgSO4 0.2 ml of 50% over 35 minutes
2. Saline infusion over 35 minutes
Comedications: All the children received oxygen, nebulised salbutamol, IV amino-
phylline, and corticosteroids
Timing of treatment: Placebo or MgSO4 was given after 60 minutes from entry to the
ED and 3 nebulised bronchodilator treatments
Outcomes Respiratory and heart rates, pulsus paradoxus (measured using a stethoscope as the
difference in systolic blood pressure between the pressure at which the first sporadic,
faint pulse sounds were heard and the pressure at which all sounds were heard), accessory
muscle usage, dyspnoea, colour, wheeze, PEFR in children 5 years of age or older, and
SaO2
Main follow-up time unclear
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised. No details
Allocation concealment (selection bias) Unclear risk No details
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Devi 1997 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind. “Decoding was done at the
completion of the study. Magnesium sul-
fate and placebo solutions (normal saline)
were prepared in the hospital pharmacy,
coded and dispensed in identical vials.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear if those taking measurements were
blind. Predetermined discharge criteria
used for sending children home from the
ED (primary outcome)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 children were excluded during the study
period as they became febrile (unclear
which group). 2/49 only 4%
Selective reporting (reporting bias) Low risk SaO2 and %PEFR in graph format only
Other bias Low risk None detected
Gürkan 1999
Methods Design: Randomised, double-blind, parallel-group, placebo-controlled trial
Emergency department in Dicle University Hospital, Turkey
Participants Participants: 20 participants were randomised to IV MgSO4 (10) and placebo (10)
Inclusion criteria: Children aged 6 to 16 with moderate to severe acute asthma exacer-
bation admitted to the ED; PEFR less than 60% of the predicted value after receiving 3
beta-2 adrenergic nebuliser treatments
Exclusion criteria: fever, systolic BP at less than 25th percentile for age, recent use of
theophylline, and history of cardiac, renal, or pulmonary disease
Interventions Treatments:
1. IV MgSO4 40 mg/kg (maximum 2 g), 20 minutes
2. Saline infusion, 20 minutes
Comedications: 3 beta-2 adrenergic nebuliser treatments
Timing of treatment: 3 beta-2 adrenergic agents at 20-minute intervals, then if PEFR
was less than 60% of the predicted value placebo or MgSO4 was administered
Outcomes Clinical asthma scores, PEFR, side effects
Main follow-up 90 minutes after start of infusion
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Gürkan 1999 (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomised. No details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The investigators performing the study
were completely blinded to the treatment
offered”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if those taking measurements were
blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No mention of non-completers
Selective reporting (reporting bias) Low risk 30- and 90-minute data provided for
named outcomes
Other bias Low risk None detected
Scarfone 2000
Methods Design: Randomised, double-blind, parallel-group, placebo-controlled trial
3 emergency departments in Philadelphia, USA
Participants Participants: 54 participants were randomised to IV MgSO4 (24) and placebo (30)
Inclusion criteria: Children aged 1 to 18 years with a past history of at least 1 episode
of wheezing who presented to the ED with a moderate to severe asthma exacerbation
(defined as a pulmonary index score of 8 to 13). To avoid enrolling young children
with bronchiolitis, the lower age limit for study inclusion was raised to 2 years from 15
November through 30 March
Exclusion criteria: More mild (pulmonary index score less than or equal to 7) or severe
(pulmonary index score greater than or equal to 14) asthma exacerbation, children who
had used corticosteroids within the preceding 72 hours, had concurrent bronchiolitis,
lobar pneumonia, croup, or suspected foreign body aspiration, a history of cystic fibrosis,
bronchopulmonary dysplasia, congenital heart disease, liver or renal disease, sickle cell
anaemia, or who were pregnant
Interventions Treatments:
1. IV MgSO4 75 mg/kg over 20 minutes
2. Saline infusion over 20 minutes
Comedications: nebulised albuterol and methylprednisolone, oxygen
Timing of treatment: After completion of a second nebulised dose of albuterol (run
immediately after first), study drug or placebo was given
Outcomes Improvement on the pulmonary index, hospitalisation rate, time required to discharge
Main follow-up 120 minutes after start of infusion
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Scarfone 2000 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no details given
Allocation concealment (selection bias) Low risk Quote from study: ”hospital pharmacists ...
created and concealed the allocation sched-
ule, broken only at study’s end“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The magnesium and placebo were identi-
cal in appearance and prepared by hospi-
tal pharmacists who also created and con-
cealed the allocation schedule, broken only
at study’s end
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk In the absence of the study investigator, ei-
ther study drugwas administered by anurse
not involved with study measurements.
Children remained in the study for 150
minutes, at which time the blinded inves-
tigator decided patient disposition, inde-
pendent of the emergency physician’s dis-
position. Guidelines for admission (satura-
tions < 92%). Discharge criteria included
sustained good aeration, absent or mini-
mal wheezing, minimal work of breathing,
and oxygen saturation greater than 95% in
room air
Incomplete outcome data (attrition bias)
All outcomes
Low risk ”One child in the placebo group required
more aggressive asthma therapy than al-
lowed for by the protocol after 95 minutes.
Another child in the magnesium group
was mistakenly given an inadequate dose
of magnesium. Importantly, there were no
changes in outcome measures when a sec-
ondary analysis was performed excluding
these 2 children
Selective reporting (reporting bias) Low risk Named outcomes well reported
Other bias Low risk None detected
BP = blood pressure
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ED = emergency department
FEV1 = forced expiratory volume in one second
FVC = forced vital capacity
IV = intravenous
MgSO4 = magnesium sulfate
O2 = oxygen
PEFR = peak expiratory flow rate
PICU = paediatric intensive care unit
SaO2 = oxygen saturation
h = hours
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bijani 2001 Participants were 15 years and above. Included in adult review. Authors cannot provide disaggregated data
Bilaceroglu 2001 Participants were 6 years and above, but only 10/81 participants were under 18 and the mean age was 36
(+/- 13.4). Included in adult review
Boonyavorakul 2000 Participants were 15 years and above. Included in adult review. Authors cannot provide disaggregated data
del Castillo Rueda 1991 Included in adult review, no data
Irazuzta 2016 Children with status asthmaticus and not a placebo comparison
Liang 1998 Population did not have asthma
Okayama 1987 Half of the participants included in the study were inpatients and could not be separated out from the
patient sample
Santana 2001 Children were all admitted to the Special Pediatric Care Unit prior to commencement of therapy (i.e. not
managed in the emergency department)
Singhi 2011 No placebo group
Skobeloff 1989 Adults
Torres 2012 Compared with usual care, not placebo
Watanatham 2015 Nebulised vs intravenous with no placebo group
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Characteristics of studies awaiting assessment [ordered by study ID]
Abd El Kader 1997
Methods “Comparative study”
Participants People with bronchial asthma
Interventions Salbutamol, ipratropium bromide, and magnesium sulfate
Outcomes Ventilatory, cardiovascular, and metabolic responses
Notes Numerous attempts made to locate paper, but no library holdings found
Characteristics of ongoing studies [ordered by study ID]
NCT01522040
Trial name or title A pilot study of magnesium infusions (drips) for moderate-to-severe pediatric asthma exacerbations
Methods Prospective randomised pilot study that seeks to address the research question: In children with moderate to
severe asthma, do intravenous magnesium infusions added to standard PICU-level asthma care significantly
decrease time from patient presentation until PICU discharge?
Participants Male and female children and adolescents aged 2 to 20 years
Interventions Drug: magnesium sulfate continuous magnesium drip, titrated to effect until patient’s symptoms improve
Placebo: Simple saline drip, without active drug
Outcomes Time to discharge, beta receptor haplotype
Starting date January 2012
Contact information Keith Cross, MD, 502-689-2457, keith.cross@louisville.edu
Kendra Sikes, 502-629-7212
Notes Updated as “Still recruiting” in February 2016 at http://www.trialdetails.com/detail/NCT01522040/Pilot-
Study-of-Magnesium-Infusions-in-Pediatric-Asthma
PICU = paediatric intensive care unit
28Intravenous magnesium sulfate for treating children with acute asthma in the emergency department (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. IV MgSO4 versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Hospital admissions 3 115 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.14, 0.74]
2 ED treatment time (minutes) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Return to ED within 48 hours 2 85 Odds Ratio (M-H, Fixed, 95% CI) 0.40 [0.02, 10.30]
4 Hospital length of stay (hours) 1 47 Mean Difference (IV, Fixed, 95% CI) -5.30 [-9.46, -1.14]
Analysis 1.1. Comparison 1 IV MgSO4 versus placebo, Outcome 1 Hospital admissions.
Review: Intravenous magnesium sulfate for treating children with acute asthma in the emergency department
Comparison: 1 IV MgSO4 versus placebo
Outcome: 1 Hospital admissions
Study or subgroup MgSO4 Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ciarallo 2000 8/16 14/14 38.7 % 0.03 [ 0.00, 0.68 ]
Ciarallo 1996 (1) 11/15 16/16 22.6 % 0.08 [ 0.00, 1.58 ]
Scarfone 2000 11/24 16/30 38.7 % 0.74 [ 0.25, 2.17 ]
Total (95% CI) 55 60 100.0 % 0.32 [ 0.14, 0.74 ]
Total events: 30 (MgSO4), 46 (Placebo)
Heterogeneity: Chi2 = 5.36, df = 2 (P = 0.07); I2 =63%
Test for overall effect: Z = 2.64 (P = 0.0083)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours MgSO4 Favours placebo
(1) discharge rate from the emergency department was the rate at which decisions to admit were reversed
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Analysis 1.2. Comparison 1 IV MgSO4 versus placebo, Outcome 2 ED treatment time (minutes).
Review: Intravenous magnesium sulfate for treating children with acute asthma in the emergency department
Comparison: 1 IV MgSO4 versus placebo
Outcome: 2 ED treatment time (minutes)
Study or subgroup MgSO4 Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Scarfone 2000 12 101 (38.7298) 15 96 (38.7298) 5.00 [ -24.40, 34.40 ]
-50 -25 0 25 50
Favours MgSO4 Favours placebo
Analysis 1.3. Comparison 1 IV MgSO4 versus placebo, Outcome 3 Return to ED within 48 hours.
Review: Intravenous magnesium sulfate for treating children with acute asthma in the emergency department
Comparison: 1 IV MgSO4 versus placebo
Outcome: 3 Return to ED within 48 hours
Study or subgroup MgSO4 Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ciarallo 1996 0/15 0/16 Not estimable
Scarfone 2000 0/24 1/30 100.0 % 0.40 [ 0.02, 10.30 ]
Total (95% CI) 39 46 100.0 % 0.40 [ 0.02, 10.30 ]
Total events: 0 (MgSO4), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours MgSO4 Favours placebo
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Analysis 1.4. Comparison 1 IV MgSO4 versus placebo, Outcome 4 Hospital length of stay (hours).
Review: Intravenous magnesium sulfate for treating children with acute asthma in the emergency department
Comparison: 1 IV MgSO4 versus placebo
Outcome: 4 Hospital length of stay (hours)
Study or subgroup MgSO4 Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Devi 1997 24 13.6 (6.8) 23 18.9 (7.7) 100.0 % -5.30 [ -9.46, -1.14 ]
Total (95% CI) 24 23 100.0 % -5.30 [ -9.46, -1.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.50 (P = 0.013)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours MgSO4 Favours placebo
A D D I T I O N A L T A B L E S
Table 1. Summary characteristics of included studies
Study ID Country
(centres)
Total N Study design Age range (yrs) Dose (infusion) Comedications
Ciarallo 1996 USA (2) 30 R, DB, PC 6 to 18 25 mg/kg
20 minutes
3 neb-
ulised bronchodilators
(albuterol, ipratropium
bromide, or both)
IV
methylprednisolone (2
mg/kg) if not yet given
corticosteroids
Ciarallo 2000 USA (1) 31 R, DB, PC 6 to 18 40 mg/kg
20 minutes
3 nebulised beta-2
adrenergic treatments
IVmethylprednisolone
(2 mg/kg) if not yet
given corticosteroids
Devi 1997 India (1) 47 R, DB, PC 1 to 12 0.2 ml of 50%
35 minutes
Nebulised salbutamol
Oxygen,
IV aminophylline, cor-
ticosteroids
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Table 1. Summary characteristics of included studies (Continued)
Gürkan 1999 Turkey (1) 20 R, DB, PC 6 to 16 40 mg/kg
20 minutes
3 beta-2 adrenergic
nebuliser treatments
Scarfone 2000 USA (3) 54 R, DB, PC 1 to 18 75 mg/kg
20 minutes
Nebulised albuterol
Oxygen, methylpred-
nisolone
R = randomised; DB = double-blind; PC = placebo-controlled
Table 2. Baseline characteristics
Study ID Inclusion Group Age (SD) % Male % PEF FEV1 Other Classification
Ciarallo
1996
PEF < 60%
predicted
(after 3 beta-
2 adrenergic
nebuliser
treatments)
MgSO4 10.8 46.7 43.8 33.1 RR = 35 BP = 120
SaO2 = 92
Moderate
Placebo 11.9 43.8 43.0 45.1 RR = 30 BP = 123
SaO2 = 94
Ciarallo
2000
PEF < 70%
predicted
(after 3 neb-
ulised bron-
chodilating
treatments)
MgSO4 10.9 68.8 29.9 28.9 BP = 120, SaO2 = 92 Severe
Placebo 12.0 50.0 33.1 31.3 BP = 114, SaO2 = 92
Devi 1997 “Inadequate
or poor re-
sponse to 3
doses of neb-
ulized salbu-
tamol”
MgSO4 6.7 79.2 30.1 NR HR = 142 Severe
Placebo 6.8 73.9 27.1 NR HR = 138
Gürkan
1999
PEF < 60%
predicted
(after 3 beta-
2 adrenergic
nebuliser
treatments)
“moder-
ate to severe
acute
asthma exac-
erbation”
MgSO4 10.4 60 46.8 NR HR = 118 BP = 118
SaO2 = 91.8
Moderate
Placebo 11.2 50 46.2 NR HR = 120 BP = 116
SaO2 = 91.4
Scarfone
2000
“moder-
ate to severe
MgSO4 6.8 58 NR NR SaO2 = 93.9 Moderate
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Table 2. Baseline characteristics (Continued)
asthma exac-
erbation”
Placebo 4.8 47 NR NR SaO2 = 94.1
SD = standard deviation; % PEF = percentage predicted peak expiratory flow; FEV1 = forced expiratory volume in one second; HR =
heart rate; RR = respiration rate; BP = systolic blood pressure; SaO2 = oxygen saturation; NR: not reported
A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL Monthly
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
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Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
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7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 magnesium*
#6 MgSO4
#7 #5 or #6
#8 #4 and #7
#9 (#8) AND (INREGISTER)
[Note: in search line #1, MISC1 refers to the field in which the reference record has been coded for condition, in this case, asthma]
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We were not able to pool more than 10 studies, and so could not create and examine a funnel plot to explore possible small-study and
publication biases. Since there were only three studies in the primary analysis (and fewer in the secondary), we did not consider the
planned subgroup and sensitivity analyses to be justified.
We did not use an independent assessor as planned to classify the study populations as having moderate, severe, and life-threatening
exacerbations because we were not able to perform the associated subgroup analysis. Instead, the classification was made for descriptive
purposes only by one of the review authors (BG). If additional studies allow the subgroup analysis to be undertaken in a future update
of this review, this will be done by an assessor blinded to the study results.
We did not specify ’Return to the emergency department within 48 hours’ as an outcome in the protocol for this systematic review,
but chose to present the results because it is related to other named outcomes which were not well reported across studies.
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